CAFFARRA MALVEZZI, Cristina
 Distribuzione geografica
Continente #
EU - Europa 624
NA - Nord America 614
AS - Asia 227
OC - Oceania 1
Totale 1.466
Nazione #
US - Stati Uniti d'America 611
IT - Italia 181
CN - Cina 176
SE - Svezia 120
IE - Irlanda 113
FI - Finlandia 103
AT - Austria 38
TR - Turchia 23
DE - Germania 22
SG - Singapore 13
IN - India 10
UA - Ucraina 10
GB - Regno Unito 8
FR - Francia 7
BE - Belgio 6
ES - Italia 5
CZ - Repubblica Ceca 4
CA - Canada 3
IR - Iran 3
RU - Federazione Russa 3
NL - Olanda 2
VN - Vietnam 2
AU - Australia 1
CH - Svizzera 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.466
Città #
Chandler 164
Dublin 113
Ann Arbor 70
Parma 68
Vienna 37
Ashburn 34
Shanghai 33
Beijing 32
Dearborn 28
Nanjing 28
Izmir 23
New York 20
Princeton 17
Nanchang 13
Bremen 12
Boardman 10
Kunming 10
Jinan 9
Wilmington 9
Jacksonville 8
Singapore 8
Des Moines 7
Helsinki 7
San Mateo 7
Brussels 6
Norwalk 6
Redmond 6
Redwood City 6
Rome 6
Seattle 6
Genoa 5
Hefei 5
Modena 5
Pune 5
Shenyang 5
Woodbridge 5
Brno 4
Frattamaggiore 4
Gainesville 4
Hebei 4
Jiaxing 4
Novellara 4
Falls Church 3
Fremont 3
Fuzhou 3
Holmfirth 3
Milan 3
Sala Baganza 3
Tianjin 3
Bologna 2
Chengdu 2
Chongqing 2
Desio 2
Dong Ket 2
Elgoibar 2
Elmsford 2
Fairfield 2
Fontevivo 2
Gorgo Al Monticano 2
Lacchiarella 2
Leawood 2
Los Angeles 2
Manchester 2
Mestre 2
Monza 2
Munich 2
Neviano degli Arduini 2
Padova 2
Reggio Nell'emilia 2
Sorbolo 2
Taiyuan 2
Treviglio 2
Turin 2
Viano 2
Zaragoza 2
Zhengzhou 2
Altrincham 1
Ardabil 1
Augusta 1
Bangalore 1
Bratislava 1
Castelfranco Emilia 1
Charlotte 1
Chicago 1
Guangzhou 1
Gunzenhausen 1
Huizen 1
Jamaica Plain 1
Lanzhou 1
Lavis 1
Mainz 1
Medesano 1
Melbourne 1
Montreal 1
New Delhi 1
Ningbo 1
Pesaro 1
Philadelphia 1
Phoenix 1
Pontremoli 1
Totale 956
Nome #
Highly-defined bioprinting of long-term vascularized scaffolds with Bio-Trap: Complex geometry functionalization and process parameters with computer aided tissue engineering 145
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 100
In-vivo vascular application via ultra-fast bioprinting for future 5D personalised nanomedicine 96
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 95
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 93
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 90
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 88
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 85
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 81
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 73
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 72
Three-Dimensional Bioprinting of Organoid-Based Scaffolds (OBST) for Long-Term Nanoparticle Toxicology Investigation 68
Alginate Formulations: Current Developments in the Race for Hydrogel-Based Cardiac Regeneration 67
Exposure to nanoparticles derived from diesel particulate filter equipped engine increases vulnerability to arrhythmia in rat hearts 65
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 57
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 57
Mitochondrial mechanosensor in cardiovascular diseases 53
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 50
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 45
null 31
Totale 1.511
Categoria #
all - tutte 4.797
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.797


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020270 43 61 7 3 8 18 48 22 20 12 13 15
2020/2021148 8 4 16 8 14 14 5 10 15 15 29 10
2021/202292 10 9 2 7 2 0 6 5 4 3 7 37
2022/2023540 43 74 46 56 45 67 1 39 136 6 22 5
2023/2024207 14 14 10 9 11 51 20 23 8 12 13 22
Totale 1.511